Share This Page
Drug Price Trends for DROSP-EE-LEVOMEF
✉ Email this page to a colleague
Average Pharmacy Cost for DROSP-EE-LEVOMEF
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DROSP-EE-LEVOMEF 3-0.02-0.451 | 00781-4075-52 | 1.39069 | EACH | 2025-02-19 |
| DROSP-EE-LEVOMEF 3-0.02-0.451 | 68180-0894-71 | 1.39069 | EACH | 2025-02-19 |
| DROSP-EE-LEVOMEF 3-0.02-0.451 | 00781-4075-15 | 1.39069 | EACH | 2025-02-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Drospirenone/Ethinyl Estradiol/Levomefolate
Introduction
Drospirenone/Ethinyl Estradiol/Levomefolate, a combination hormonal contraceptive, is widely used for various indications including birth control, treatment of premenstrual dysphoric disorder (PMDD), moderate acne, and folate supplementation. Here is a comprehensive market analysis and price projection for this medication.
Market Size and Growth
The market for Drospirenone/Ethinyl Estradiol/Levomefolate tablets is expected to experience significant growth over the next few years. As of 2023, the market was valued at approximately $25 billion and is projected to reach $45 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 8%[3].
Drivers of Growth
Several factors are driving the growth of this market:
- Increasing Demand for Birth Control: The global demand for effective birth control methods continues to rise, driven by increasing awareness and accessibility of contraceptive options.
- Treatment of PMDD and Acne: The medication's efficacy in treating PMDD and moderate acne in women adds to its market demand.
- Folate Supplementation: The inclusion of levomefolate, a form of folic acid, helps in preventing neural tube defects, making it a preferred choice for women of reproductive age[1][4].
Market Segmentation
The Drospirenone/Ethinyl Estradiol/Levomefolate market is segmented based on type, application, and geography.
Type
The market includes various brand names such as Yaz, Yasmin, Ocella, and Loryna, among others. Generic versions are also widely available, contributing to the market's diversity[2].
Application
The primary applications include:
- Birth Control: Preventing pregnancy by inhibiting ovulation.
- PMDD: Treating symptoms of premenstrual dysphoric disorder.
- Moderate Acne: Treating acne in women at least 14 years old.
- Folate Supplementation: Raising folate levels to prevent neural tube defects[1][4].
Geography
The market is global, with significant demand in regions with high population growth and increasing awareness of reproductive health. Key players operate across various countries, with regional customization of market data available[3].
Key Players
The market is dominated by several major pharmaceutical companies, including:
- Camber Pharmaceuticals
- Aurobindo Pharma
- Teva Generics
- Glenmark Pharmaceuticals
- Xiromed
- Wellona Pharma
- Barr Pharmaceuticals, Inc.
- Hetero Drugs
- MYLAN LABS LTD.
- Bayer Weimar GmbH und Co. KG[3].
These companies are evaluated based on their product offerings, financial performance, strategic approaches, and geographical presence.
Pricing and Cost Analysis
The cost of Drospirenone/Ethinyl Estradiol/Levomefolate tablets can vary depending on the pharmacy and the specific formulation.
Current Pricing
- A supply of 28 tablets (3 mg drospirenone and 0.02 mg or 0.03 mg ethinyl estradiol) can cost between $28.27 and $29.51 for cash-paying customers. Prices can be lower with the use of discount cards or coupons[2].
Price Projections
Given the market growth and increasing demand, prices may stabilize or slightly increase over the forecast period. However, competition from generic versions and patient assistance programs can help keep prices manageable for consumers.
Patient Assistance Programs
While there are no specific patient assistance programs available for this medication, healthcare providers may have information on local programs or discounts that can reduce the cost for uninsured or under-insured patients[2].
Market Trends
Increasing Generic Competition
The availability of generic versions of Drospirenone/Ethinyl Estradiol/Levomefolate is expected to increase, which could lead to competitive pricing and potentially lower costs for consumers.
Regulatory Environment
Regulations and government spending on healthcare can influence market dynamics. For instance, policies supporting reproductive health and family planning can boost the demand for this medication[3].
Consumer Behavior
Consumer awareness and preference for hormonal contraceptives, along with the convenience of a single medication addressing multiple health issues, drive the market's growth.
Challenges and Risks
Vascular Risks
Drospirenone-containing contraceptives may be associated with a higher risk of venous thromboembolism (VTE) compared to other progestins. This risk needs to be managed through careful patient selection and monitoring[1].
Breastfeeding Considerations
The medication is not recommended for breastfeeding women due to the lack of adequate studies on infant risk[4].
Conclusion
The market for Drospirenone/Ethinyl Estradiol/Levomefolate is poised for significant growth driven by its multiple indications, increasing demand for birth control, and the inclusion of folate supplementation. While pricing may vary, the availability of generic versions and patient assistance programs can help make the medication more accessible.
Key Takeaways
- Market Growth: Expected to reach $45 billion by 2031 with a CAGR of 8%.
- Key Applications: Birth control, PMDD, moderate acne, and folate supplementation.
- Key Players: Major pharmaceutical companies including Camber Pharmaceuticals, Aurobindo Pharma, and Bayer.
- Pricing: Current prices range from $28.27 to $29.51 for a 28-tablet supply.
- Challenges: Vascular risks and considerations for breastfeeding women.
FAQs
What are the primary indications for Drospirenone/Ethinyl Estradiol/Levomefolate?
The primary indications include preventing pregnancy, treating symptoms of premenstrual dysphoric disorder (PMDD), treating moderate acne, and raising folate levels to prevent neural tube defects[1][4].
How does Drospirenone/Ethinyl Estradiol/Levomefolate work?
It works by stopping a woman's egg from fully developing each month, thus preventing fertilization and pregnancy. It also treats PMDD and acne through hormonal regulation[4].
What are the potential risks associated with Drospirenone/Ethinyl Estradiol/Levomefolate?
The medication may be associated with a higher risk of venous thromboembolism (VTE) compared to other progestins. It is also not recommended for breastfeeding women due to the lack of adequate studies on infant risk[1][4].
Are there any patient assistance programs available for Drospirenone/Ethinyl Estradiol/Levomefolate?
Currently, there are no specific patient assistance programs available for this medication, but healthcare providers may have information on local programs or discounts[2].
How much does a supply of Drospirenone/Ethinyl Estradiol/Levomefolate typically cost?
A supply of 28 tablets can cost between $28.27 and $29.51 for cash-paying customers, with potential discounts available through various programs[2].
What are the brand names for Drospirenone/Ethinyl Estradiol/Levomefolate?
Common brand names include Yaz, Yasmin, Ocella, and Loryna, among others[2].
Sources
- DailyMed: DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM kit.
- Drugs.com: Drospirenone/ethinyl estradiol Prices, Coupons, Copay Cards & Patient Assistance.
- Verified Market Reports: Drospirenone and Ethinylestradiol Tablets Market Size.
- Mayo Clinic: Drospirenone, ethinyl estradiol, and levomefolate (oral route).
More… ↓
